Market closedNon-fractional

Cardiol Therapeutics/CRDL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Cardiol Therapeutics

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Ticker

CRDL

Sector

Healthcare

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

Oakville, Canada

Employees

-

CRDL Metrics

BasicAdvanced
$135M
Market cap
-
P/E ratio
-$0.34
EPS
0.63
Beta
-
Dividend rate
$135M
0.63
2.807
2.646
0.751
0.833
-45.35%
-92.11%
9.24
9.33
-7.697
0.45%
-17.69%

What the Analysts think about CRDL

Analyst Ratings

Majority rating from 2 analysts.
Buy

CRDL Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$9.1M
19.74%
Profit margin
0.00%
NaN%

CRDL Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 7.69%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.12
-$0.09
-$0.12
-$0.14
-
Expected
-$0.13
-$0.12
-$0.12
-$0.13
-$0.13
Surprise
-4.00%
-25.00%
0.00%
7.69%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Cardiol Therapeutics stock?

Cardiol Therapeutics (CRDL) has a market cap of $135M as of July 06, 2024.

What is the P/E ratio for Cardiol Therapeutics stock?

The price to earnings (P/E) ratio for Cardiol Therapeutics (CRDL) stock is 0 as of July 06, 2024.

Does Cardiol Therapeutics stock pay dividends?

No, Cardiol Therapeutics (CRDL) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Cardiol Therapeutics dividend payment date?

Cardiol Therapeutics (CRDL) stock does not pay dividends to its shareholders.

What is the beta indicator for Cardiol Therapeutics?

Cardiol Therapeutics (CRDL) has a beta rating of 0.63. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Cardiol Therapeutics stock

Buy or sell Cardiol Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing